Shots: The sBLA is based on P-III IMbrave150 study involve assessing of Tecentriq (1200mg, IV) + Avastin (IV, 15 mg/kg) vs Sorafenib (PO, 400mg, bid) in 501 patients in a […]readmore
Tags : Avastin
Shots: Innovent to receive $45M as upfront, development & regulatory milestone and royalties on sales of the therapy in the licensed territories while Coherus plans to file BLA to the […]readmore
Shots: The P-III IMbrave150 study involve assessing of Tecentriq (1200mg, IV) + Avastin (IV, 15 mg/kg) vs Sorafenib (PO, 400mg, bid) in 501 patients in a ratio 2:1 with unresectable […]readmore
Shots: The P-III IMbrave150 study involve assessing of Tecentriq (1200 mg on day 1 of each 21-day cycle) in combination with Avastin (15 mg/kg on day 1 of each 21-day […]readmore
Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing […]readmore
Shots: Cipla to get exclusive commercialization rights for Bio-Thera’s BAT1706 in certain countries. Bio-Thera will be responsible for its development & product approval with FDA & EMA In 2020, Bio-Thera […]readmore
Shots: The FDA’s BT designation is based on P-Ib (NCT02715531) study assessing Tecentriq (1200mg) + Avastin (15 mg/kg) in 23 patients with advanced or metastatic first-line HCC The P-Ib study […]readmore